Abstract 2022-RA-1607-ESGO Figure 2

Conclusion We have demonstrated that performing IDS within four weeks after NACT may be associated with better survival outcomes.

2022-RA-1611-ESGO

CHECKPOINT INHIBITION IN OVARIAN CANCER WORKS – A CASE REPORT OF COMPLETE RESPONSE TO IMMUNE CHECKPOINT INHIBITION IN A PLATINUM RESISTANT PRIMARY OVARIAN CANCER PATIENT WITH LYNCH SYNDROME

1 Lukas Chinczewski, 2 Felix Wilhelm Feldhaus, 3 Wolfgang Daniel Schmitt, 4 Elena Ioana Braicu, 4 Eva Roser, 1 Talal Sehouli. 1 Department of Gynecology, Charité – Universitätsmedizin Berlin, Berlin, Germany; 2 Radiology, Charité – Universitätsmedizin Berlin, Berlin, Germany; 3 Pathology, Charité – Universitätsmedizin Berlin, Berlin, Germany; 4 Gynecology, Charité – Universitätsmedizin Berlin, Berlin, Germany

Introduction/Background Lynch syndrome is a secondary cause for hereditary ovarian cancer after BRCA mutation. Germline mutations in the DNA-mismatch repair genes cause tumorigenesis and a high immunogenicity. Recent studies showed a promising use of immunotherapy in MMR deficient (MMRd) tumors. We present a case of a patient with LS associated OC and a complete response to pembrolizumab.

Methodology x

Results A 44-year old patient was admitted to the hospital with lower abdominal pain. The patient’s history showed LS with a germline mutation in the MSH2-gene. Initial diagnostics showed a pelvic tumor mass and a highly elevated cancer antigen 125. After debulking surgery, histopathological findings showed a high grade serous OC with a mutation in the MSH2 and MSH6-genes. Only 5 weeks after operation with no residual tumor mass a quick and significant intraabdominal progression of the disease was diagnosed. Adjuvant therapy with carboplatin and paclitaxel in a weekly course did not lead to sustainable response. An anti-PD-L1 antibody therapy with pembrolizumab was initiated. After only 2 courses of therapy the laboratory results and clinical status of the patient improved tremendously. Shortly after a complete response was detected and until today for 28 cycles immune checkpoint inhibition therapy is ongoing. The patient remains tumor free for 21 months now.

Conclusion Recent studies suggest a promising effect of checkpoint inhibition within MMRd tumors. OC on the other hand does not seem to show an overall good response to immunotherapy. The significance of germline compared to somatic mutations has not yet been investigated in prior studies sufficiently. To our knowledge, this is the first case with complete response to checkpoint inhibition in OC associated with LS. Comprehensive testing for germline mutations should be established. Regarding Lynch syndrome associated ovarian cancer, immune checkpoint inhibition is an efficient therapy in tumors nonresponsive to standard therapy.

2022-RA-1621-ESGO

ROLE OF PET-CT AND CECT IN CALCULATING PREOPERATIVE PCI IN PATIENTS WITH EPITHELIAL OVARIAN CANCER

1 Monica Gutierrez Martínez, 1 Felix Boria, 1 Lidia Sancho, 1 Andrés Alcazar, 1 Luis Chiva, 2 Daniel Vázquez, 1 Teresa Castellanos. 1 Clínica Universidad de Navarra, Madrid, Spain; 2 Clínica Universidad de Navarra, Clínica Universidad de Navarra, Spain

Introduction/Background The objectives are to compare the efficacy between preoperative PET/CT and CeCT findings according with the surgical findings in patients that underwent surgery for epithelial ovarian cancer treatment and to evaluate the correlation between preoperative PCI calculated in both PET/CT and CeCT with surgery.

Methodology Retrospective unicentric observational study reviewing data of 30 patients diagnosed with epithelial ovarian cancer (primary or recurrence) and operated between July 2018-February 2021 in Clínica Universidad de Navarra. Every patient underwent PET/CT and CeCT. PET/CT was independently evaluated by a nuclear medicine doctor (PET-CT) and CeCT by an expert radiologist in gynecologic malignancies. PCI in surgery was calculated by two different gynecologic oncologists. If there was any discordance between them, a media between both scores was applied. Medical history and demographic data, preoperative FIGO stage, PET/CT findings, CT findings final pathology diagnosis, type of surgery and perioperative details were reviewed. Intraoperator correlation coefficient was calculated to compare the PCI obtained preoperatively in PET/CT and CeCT to the PCI obtained in the final surgery.

Results The interclass correlation coefficient in the global cohort of patients compared to the PCI calculated intraoperatively was 0.867 for CeCT and 0.807 for PET-CT. Regarding the prediction of complete cytoreduction, the area under the curve in the CeCT was 0.659 and 0.690 in the PET-CT.

Conclusion Despite the small sample size, this initial study highlights that CeCT is more effective in calculating PCI preoperatively, however, PET-CT is better at predicting complete cytoreduction. Further validation in larger series is needed.

2022-RA-1622-ESGO

MALIGNANT BRENNER TUMOR OF THE OVARY: CASE SERIES OF ONE SINGLE INSTITUTE

1 Amani Jellali, 1 Malek Bouhani, 1 Takoua Chalouati, 1 Saïda Sakhrî, 1 Ines Houissa, 2 Ghada Sahraoui, 1 Riadh Chargui, 1 Khaled Rahal. 1 Department of surgical oncology, Salah Azâiez Institute, Tunisia, Tunisia; 2 Pathology department, Salah Azâiez Institute, Tunis, Tunisia

Introduction/Background Malignant Brenner tumor of the ovary is a rare benign neoplasm. The literature is scarce in the case series of one single institute and we aim to report the clinical features and survival outcome of our single case. To the best of our knowledge, this is the first case series of a single institute. The recent literature offers disappointing results for the surgical management of malignant Brenner tumor of the ovary. Malignant Brenner tumor of the ovary is seldom encountered in clinical practice and, currently, the stage at diagnosis and the surgical approach is still controversial. The purpose of this study is to offer a comprehensive analysis of malignant Brenner tumor of the ovary.

Methodology A 43-year-old woman with a history of hypertension presented with a palpable mass in the right lower abdomen. The patient was admitted to our hospital for workup of the mass. A computed tomography (CT) scan of the abdomen and pelvis was performed and revealed a heterogeneous mass in the right ovary measuring 13 × 11 × 10 cm with multiple enhancing nodules within. The mass was located in the adnexa and there was no evidence of extraovarian extension. The patient underwent a laparoscopic right salpingo-oophorectomy. Pathological examination of the specimen revealed a malignant Brenner tumor of the ovary.

Results The patient tolerated the surgery well and was discharged home on postoperative day 1. Four weeks after surgery, the patient underwent a second-look laparoscopy. Pathological examination of the second-look laparoscopy specimen revealed no evidence of residual disease. The patient was discharged home on postoperative day 2. The patient was seen in the outpatient clinic every 3 months after surgery. At the last follow-up, the patient was disease-free for 24 months.

Conclusion Malignant Brenner tumor of the ovary is a rare benign neoplasm. The literature is scarce in the case series of one single institute and we aim to report the clinical features and survival outcome of our single case. To the best of our knowledge, this is the first case series of a single institute. The recent literature offers disappointing results for the surgical management of malignant Brenner tumor of the ovary. Malignant Brenner tumor of the ovary is seldom encountered in clinical practice and, currently, the stage at diagnosis and the surgical approach is still controversial. The purpose of this study is to offer a comprehensive analysis of malignant Brenner tumor of the ovary.